Search This Section
3 Aug 2020
DaHui advised Amwise Diagnostic on its recent Series B financing of over USD 10 million, led by Simcere Diagnosis, an affiliate of the Simcere Group. Amwise Diagnostic is a leader in precision medicine technology for cancer. Its patented genetic analysis technologies assist doctors and patients in determining the most appropriate individualized treatment strategy. The funds raised will be used to promote the Asian Breast Cancer Recurrence Risk Assessment and Detection Program, RecurIndex in the Chinese market, to bring world-leading diagnostic products and services directly to Chinese breast cancer patients at home.
DaHui represented Amwise Diagnostic on the transaction, with the team being led by partner Xikang Wang.